Selpercatinib is approved by the USFDA for medullary thyroid cancer with a RET mutation

  On September 27, 2024, the Food and Drug Administration conferred traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients aged 2 years and older diagnosed with advanced or ..

Selpercatinib is approved by FDA for RET fusion-positive thyroid cancer

  May 2024: The Food and Drug Administration has officially approved selpercatinib (Retevmo, Eli Lilly and Company) for the treatment of advanced or metastatic RET fusion-positive thyroid cancer in both adult and pediatric..

Cabozantinib, COSMIC-311, VEGFR-targeted therapy

Cabozantinib is approved for differentiated thyroid cancer

October 2021: Cabozantinib (Cabometyx, Exelixis, Inc.) has been approved by the Food and Drug Administration for adult and paediatric patients 12 years of age and older who have locally advanced or metastatic differentiated thyroi..

Lenvima

Anti-cancer drug Lenvatinib approved for clinical treatment of thyroid cancer

Lenvatinib (Lenvima) New oral anticancer drug Lenvima (lenvatinib) has recently been approved by Japan for the treatment of unresectable thyroid cancer. This is another important market that the drug has captured since it was ap..